华东医药：DR10624注射液药品临床试验申请获美国FDA批准

Core Viewpoint - The company announced that its subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has received approval from the U.S. FDA to conduct clinical trials for the drug DR10624, which targets severe hypertriglyceridemia (SHTG) [1] Group 1 - The clinical trial application for DR10624 injection has been approved by the U.S. FDA [1] - The approved indication for DR10624 is severe hypertriglyceridemia (SHTG) [1] - The approval allows the company to initiate clinical trials in the United States [1]